The Caring Ambassadors Program provides this website to help you and your loved ones understand your disease
and some of the health care option available to you.

Our three main methods to fight lung cancer are to Empower patients and providers with access to free educational materials, and resources; to Educate communities about the importance of screening and to share current information with patients and their families; and to Advocate for access to screening and treatment for lung cancer for all communities. Knowledge empowers you to ask the necessary questions to become your own best advocate. When your questions have been asked and answered, you and your health care providers will be in the best possible situation to determine the best treatment approach for you.

Lung Cancer News
Week Ending July 15, 2019

Immunohistochemistry to Assess MET Status Is a Poor Screen for Actionable MET Alterations in Lung Adenocarcinoma
According to researchers, some lung adenocarcinoma tumor specimens that are positive for a known oncogenic molecular alteration in MET are negative for MET overexpression by immunohistochemistry (IHC). The findings of this study were published online in the Journal of Thoracic Oncology.

Winship Cancer Institute of Emory University has been awarded NCI’s five-year, $9.7 million Specialized Program of Research Excellence grant  to study new approaches for lung cancer treatment.
This new grant (P50CA217691) is the first to be awarded in the state of Georgia and one of four SPORE grants in the U.S. dedicated to lung cancer.

Efforts Continue to Increase Lung Cancer Screening
Patients who are between the ages of 55 and 74 years, have a 30 pack-year history, and have not quit smoking within the last 15 years are encouraged to undergo lung cancer screening, according to Inga T. Lennes, MD, MBA, MPH.

FDA grants orphan drug designation to Imfinzi for small cell lung cancer
Durvalumab (Imfinzi, AstraZeneca) — a human monoclonal antibody that binds to PD-L1 — already is approved in the United States for treatment of patients with unresectable, stage III non-small cell lung cancer who underwent chemotherapy and radiation. The agent also is approved for previously treated patients with advanced bladder cancer.

Frontline Immunotherapy Approval in Small Cell Lung Cancer Sets New Precedent for Progress
Checkpoint inhibitors have propelled the field of small cell lung cancer (SCLC) forward, and further exploration into novel targets like DLL3, PARP, and activated transcription may move the needle even further, said Anna F. Farago, MD, PhD.

Pairing targeted drugs could overcome breast, lung cancer treatment resistance
A new study has shown that targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types.

Coordinated Efforts Are Paramount in Lung Cancer Molecular Testing
Treatment of lung cancer is far more complex and effective than it was years ago, thanks, in part, to molecular testing strategies that are shaping the realm of personalized care.

Updated 3-Year Data Confirm Prolonged Survival Benefit With Durvalumab in Stage III NSCLC
Data from a 3-year update of the phase III PACIFIC trial confirmed an improvement in overall survival (OS) with treatment of durvalumab (Imfinzi) in patients with unresectable, stage III non–small cell lung cancer (NSCLC) who did not progress after chemoradiotherapy.

Mind the gap: Precision medicine shortcomings in NSCLC
ASCO abstracts highlight new molecular targets in advanced NSCLC, but we’re failing to execute on the best care available now.

Boulder-based Biodesix announces partnership to develop liquid biopsy
Boulder-based lung cancer diagnostic company Biodesix announced Tuesday that it has entered into an agreement with Thermo Fisher Scientific to bring a blood-based DNA sequencing analysis for liquid biopsies to the general public.

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025
Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca announced the Lung Ambition Alliance, a new partnership with a bold ambition to eliminate lung cancer as a cause of death. The first goal of the Alliance will be to double five-year survival for patients with lung cancer by 2025.

Video:
STUDY: Earlier lung cancer screenings could save up to 12,000 lives per year

Integrative Health & Medicine News
Week Ending July 15, 2019

Nutrition Key to Patient Recovery From Injury, Illness
“When people are recovering from an illness or injury, they often don’t think of nutrition, but it may be key to getting their health back.”

7 clinically proven natural remedies
“It may be hard to imagine, but in the days before prescription medications, people turned to natural remedies to treat conditions such as infections and toothaches. Currently, about 4 out of 10 adults still turn to alternative therapies and the like, including herbal supplements, to treat what ails them.”

MY CHOICES: A Planner for
Healing is now available
for download!

Order Educational Materials

Free Brochures & Materials